1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ImpediMed Limited

ImpediMed Limited

IPD.AX
ImpediMed LimitedAU flagAustralian Securities Exchange
0.01
AUD
+0.00
- -
10.47MMarket Cap
ImpediMed Limited
IPD.AX
(Australian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.03
0.02
0.02
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
0.01
Revenue per Share
-0.09
-0.09
-0.07
-0.04
-0.04
-0.05
-0.08
-0.07
-0.07
-0.06
-0.04
-0.02
-0.01
-0.01
-0.01
-0.01
Basic EPS, GAAP
-0.09
-0.07
-0.07
-0.04
-0.03
-0.04
-0.07
-0.07
- -
-0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.16
0.11
0.08
0.03
0.04
0.08
0.21
0.11
0.04
-0.02
- -
- -
0.01
0.01
- -
-0.01
Book Value per Share
0.16
0.12
0.09
0.04
0.05
0.12
0.25
0.14
0.08
0.03
0.04
0.02
0.02
0.03
0.01
- -
Tangible Book Value per Share
123
158
173
195
211
281
335
393
395
397
595
1,202
1,679
1,800
2,022
2,019
Basic Weighted Avg Shares
4
4
3
3
4
5
6
6
5
4
6
8
10
11
10
13
Sales/Revenue/Turnover
-321.3
-392.44
-457.22
-347.75
-227.26
-312.65
-452.06
-533.33
-638.71
-659.15
-448.84
-276.22
-205.21
-204.4
-241.76
-190.44
Operating Margin (%)
1
1
1
- -
- -
- -
- -
- -
- -
1
1
2
3
2
2
5
Depreciation Expense
-11
-15
-12
-8
-8
-15
-26
-28
-27
-24
-21
-21
-20
-21
-20
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-313.33
-381.32
-419.08
-309.7
-225.36
-305.47
-448.63
-478.17
-566.48
-588.65
-375.43
-247.89
-189.37
-182.43
-196.86
-182.62
Profit Margin (%)
19
18
15
8
11
32
82
56
32
10
20
18
39
46
25
22
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
1
14
LT Debt
22
21
17
11
14
35
85
59
36
16
27
26
51
61
41
20
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-85.01
-79.86
-78.37
-90.1
-123.2
-94.26
-55.97
-49.49
-94.32
- -
- -
- -
- -
-98.09
-131.41
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.19%
5.96%
-49.69%
Free Cash Flow
13.21%
5.03%
-68.15%
Net Income, GAAP
6.76%
1.99%
17.42%
Sales/Revenue/Turnover
12.21%
19.09%
26.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
11
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
13

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Natus Medical Incorporated (NTUS)
Zimmer Biomet Holdings, Inc. (ZBH.SW)
Ningbo David Medical Device Co., Ltd. (300314.SZ)
Hamilton Thorne Ltd. (HTL.V)
Aquarius Surgical Technologies Inc. (AQQRF)
ATS Medical, Inc. (ATSI)
Business
ImpediMed Limited ImpediMed Limited is an Australian Stock Exchange-listed medical technology company that designs and manufactures devices employing bioimpedance spectroscopy (BIS) technology for the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients; its core products include the SOZO Digital Health Platform, which provides comprehensive body composition analysis, fluid status monitoring, and L-Dex analysis for early detection of lymphedema, particularly breast cancer-related lymphedema (BCRL), as well as specialized devices for lymphedema screening and management in oncology, heart failure, and hydration assessment settings. The company targets healthcare professionals in breast cancer centers, hospitals, and clinics, serving patients undergoing cancer treatment, surgical procedures, and chronic condition management; it operates globally with headquarters in Brisbane, Australia, and additional offices in the United States (Carlsbad, California, and Bloomington, Minnesota) and Europe. Founded in 1999, ImpediMed Limited drives innovation focused on secondary lymphedema challenges, with its SOZO platform recognized in updated 2024 National Accreditation Program for Breast Centers (NAPBC) standards as an evidence-based tool for lymphedema prevention. In February 2025, the company secured a five-year $15 million growth capital facility from SWK Holdings Corporation SWK Holdings Corporation, providing non-dilutive funding flexibility to accelerate commercialization of the SOZO platform and expand market adoption amid increasing U.S. payer coverage for over 258 million lives; this strategic financing, advised by Armentum Partners, supports ongoing execution of its growth strategy without dilution to shareholders.

Company News

APIChatGPT